Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Cancer research needs a better mapNature (London), 2021-01, Vol.589 (7843), p.514-516 [Peer Reviewed Journal]COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Jan 28, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-021-00182-0 ;PMID: 33500573Full text available |
|
2 |
Material Type: Article
|
Cancer Cell Lines Are Useful Model Systems for Medical ResearchCancers, 2019-08, Vol.11 (8), p.1098 [Peer Reviewed Journal]2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11081098 ;PMID: 31374935Full text available |
|
3 |
Material Type: Article
|
Are innovation and new technologies in precision medicine paving a new era in patients centric care?Journal of translational medicine, 2019-04, Vol.17 (1), p.114-114, Article 114 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1479-5876 ;EISSN: 1479-5876 ;DOI: 10.1186/s12967-019-1864-9 ;PMID: 30953518Full text available |
|
4 |
Material Type: Article
|
Gastric cancerThe Lancet (British edition), 2020-08, Vol.396 (10251), p.635-648 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31288-5Full text available |
|
5 |
Material Type: Article
|
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseasesNature reviews. Drug discovery, 2019-04, Vol.18 (4), p.295-317 [Peer Reviewed Journal]Copyright Nature Publishing Group Apr 2019 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-018-0008-x ;PMID: 30610225Full text available |
|
6 |
Material Type: Article
|
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesBioMed research international, 2016-01, Vol.2016, p.8797206-15 [Peer Reviewed Journal]Copyright © 2016 Elizabeth E. Hull et al. ;COPYRIGHT 2016 Hindawi Limited ;Copyright © 2016 Elizabeth E. Hull et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ;Copyright © 2016 Elizabeth E. Hull et al. 2016 ;ISSN: 2314-6133 ;EISSN: 2314-6141 ;DOI: 10.1155/2016/8797206 ;PMID: 27556043Full text available |
|
7 |
Material Type: Article
|
Lysosomal lipid peroxidation mediates immunogenic cell deathThe Journal of clinical investigation, 2023-04, Vol.133 (8), p.1-3 [Peer Reviewed Journal]Copyright American Society for Clinical Investigation Apr 2023 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JG164596Full text available |
|
8 |
Material Type: Article
|
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapyJournal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002071 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. 2021 ;ISSN: 2051-1426 ;EISSN: 2051-1426 ;DOI: 10.1136/jitc-2020-002071 ;PMID: 33858848Full text available |
|
9 |
Material Type: Article
|
An androgen receptor N-terminal domain antagonist for treating prostate cancerThe Journal of clinical investigation, 2013-07, Vol.123 (7), p.2948-2960 [Peer Reviewed Journal]COPYRIGHT 2013 American Society for Clinical Investigation ;COPYRIGHT 2013 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jul 2013 ;Copyright © 2013, American Society for Clinical Investigation 2013 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci66398 ;PMID: 23722902Full text available |
|
10 |
Material Type: Article
|
Drugging the 'undruggable' cancer targetsNature reviews. Cancer, 2017-08, Vol.17 (8), p.502-508 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Aug 2017 ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/nrc.2017.36 ;PMID: 28643779Full text available |
|
11 |
Material Type: Article
|
Next-generation characterization of the Cancer Cell Line EncyclopediaNature (London), 2019-05, Vol.569 (7757), p.503-508 [Peer Reviewed Journal]COPYRIGHT 2019 Nature Publishing Group ;Copyright Nature Publishing Group May 23, 2019 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-019-1186-3 ;PMID: 31068700Full text available |
|
12 |
Material Type: Article
|
Gasdermin E suppresses tumour growth by activating anti-tumour immunityNature (London), 2020-03, Vol.579 (7799), p.415-420 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Copyright Nature Publishing Group Mar 19, 2020 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2071-9 ;PMID: 32188940Full text available |
|
13 |
Material Type: Article
|
Transforming Growth Factor-β Signaling in Immunity and CancerImmunity (Cambridge, Mass.), 2019-04, Vol.50 (4), p.924-940 [Peer Reviewed Journal]2019 ;Copyright © 2019. Published by Elsevier Inc. ;Copyright Elsevier Limited Apr 16, 2019 ;ISSN: 1074-7613 ;EISSN: 1097-4180 ;DOI: 10.1016/j.immuni.2019.03.024 ;PMID: 30995507Full text available |
|
14 |
Material Type: Article
|
G-quadruplex structures mark human regulatory chromatinNature genetics, 2016-10, Vol.48 (10), p.1267-1272 [Peer Reviewed Journal]Copyright Nature Publishing Group Oct 2016 ;ISSN: 1061-4036 ;EISSN: 1546-1718 ;DOI: 10.1038/ng.3662 ;PMID: 27618450Full text available |
|
15 |
Material Type: Article
|
Nanomedicine: is it lost in translation?Therapeutic delivery, 2018-03, Vol.9 (4), p.269-285 [Peer Reviewed Journal]2018 Newlands Press ;Copyright Newlands Press Mar 2018 ;ISSN: 2041-5990 ;EISSN: 2041-6008 ;DOI: 10.4155/tde-2017-0118 ;PMID: 29495928Full text available |
|
16 |
Material Type: Article
|
Novel mechanisms and functions of complementNature immunology, 2017-12, Vol.18 (12), p.1288-1298 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Dec 2017 ;ISSN: 1529-2908 ;EISSN: 1529-2916 ;DOI: 10.1038/ni.3858 ;PMID: 29144501Full text available |
|
17 |
Material Type: Article
|
Circular RNAs: a new frontier in the study of human diseasesJournal of Medical Genetics, 2016-06, Vol.53 (6), p.359-365 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0022-2593 ;EISSN: 1468-6244 ;DOI: 10.1136/jmedgenet-2016-103758 ;PMID: 26945092 ;CODEN: JMDGAEFull text available |
|
18 |
Material Type: Article
|
Optimizing oncolytic virotherapy in cancer treatmentNature reviews. Drug discovery, 2019-09, Vol.18 (9), p.689-706 [Peer Reviewed Journal]Copyright Nature Publishing Group Sep 2019 ;Springer Nature Limited 2019. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-019-0029-0 ;PMID: 31292532Full text available |
|
19 |
Material Type: Article
|
PPARγ is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosisPLoS pathogens, 2018-06, Vol.14 (6), p.e1007100-e1007100 [Peer Reviewed Journal]2018 Arnett et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Arnett et al 2018 Arnett et al ;ISSN: 1553-7374 ;ISSN: 1553-7366 ;EISSN: 1553-7374 ;DOI: 10.1371/journal.ppat.1007100 ;PMID: 29928066Full text available |
|
20 |
Material Type: Article
|
Cytokines in Cancer ImmunotherapyCold Spring Harbor perspectives in biology, 2018-12, Vol.10 (12), p.a028472 [Peer Reviewed Journal]Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved. ;Copyright Cold Spring Harbor Laboratory Press Dec 2018 ;2018 ;ISSN: 1943-0264 ;EISSN: 1943-0264 ;DOI: 10.1101/cshperspect.a028472 ;PMID: 29101107Full text available |